Incytevs.Neurocrine Biosciences
INCY vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte is about 1.6× larger than Neurocrine Biosciences by market cap; Incyte trades at the lower P/E (15.1 vs 22.0); year to date, Incyte leads (+29.6% vs +7.9%).
Side by side
| INCY | NBIX | |
|---|---|---|
| Market cap | $24.4B | $15.5B |
| Price | $129.72 | $153.37 |
| Today | +1.4% | +0.2% |
| Return YTD | +29.6% | +7.9% |
| Return 1Y | +50.5% | +13.0% |
| P/E | 15.1 | 22.0 |
| P/S | 4.2 | 4.6 |
| P/B | 3.8 | 4.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More INCY & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where INCY and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →